Fecal propionate is a signature of insulin resistance in polycystic ovary syndrome

作者：Sitong Dong, Xinrui Yao, Jiao Jiao, Bei Lin, Fujie Yan, Xiuxia Wang · 发表于：Frontiers in Cellular and Infection Microbiology · 年份：2025 · DOI：10.3389/fcimb.2024.1394873 · 被引用次数：6 · 研究领域：Ovarian function and disorders、Gut microbiota and health、Gastrointestinal motility and disorders

Objective To investigate the roles of fecal short-chain fatty acids (SCFAs) in polycystic ovary syndrome (PCOS). Methods The levels of SCFAs (acetate, propionate, and butyrate) in 83 patients with PCOS and 63 controls were measured, and their relationships with various metabolic parameters were analyzed. Intestinal microbiome analysis was conducted to identify relevant bacteria. The study took place at the Center for Reproductive Medicine at Shengjing Hospital of China Medical University in Shenyang, from 5 February to 23 May 2023. Logistic regression analyses were used to investigate the relationships between SCFAs, PCOS, and PCOS-related insulin resistance (IR). Differences in bacterial populations between women with PCOS-IR and those with PCOS-non-insulin resistance (NIR) were identified using linear discriminant analysis effect Size (LEfSe). The relationships between bacteria and fecal propionate levels were explored through linear regression analyses. The potential of fecal propionate and microbial profiles as biomarkers for insulin resistance in PCOS patients was assessed using receiver operating characteristic (ROC) curve analysis. Results Higher fecal propionate levels were observed in patients with PCOS compared to controls ( p = 0.042) and in PCOS-IR compared to PCOS-NIR ( p = 0.009). There was no significant difference in fecal propionate levels between the IR and NIR subgroups of women in the control group ( p > 0.05). Additionally, higher fecal propionate ...